Loading tape…Loading tape…
ZBH
ZBH
ZBH
A Zacks report asks: Should Value Investors Buy Zimmer Biomet (ZBH) Stock? Relevant fundamentals for the medical technology company include an annual revenue of 8,231,500,000 and a market cap of 18,972,818,340. Zimmer Biomet Holdings Inc currently trades with a PE ratio of 23.75, backed by a TTM EPS of 4.20 and a free cash flow yield of 9.65%.
Based on zacks.comZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet Announces Webcast and Conference Call of Third Quarter 2026 Financial Results
Critical Review: Zimmer Biomet (NYSE:ZBH) and Butterfly Network (NYSE:BFLY)
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Revenue & Net Income (5Y)
EPS & Growth (5Y)
Free Cash Flow (5Y)
Capital Returns
Operating & Net Margin (5Y)
CapEx vs. Free Cash Flow (5Y)
Capital Allocation (5Y)
R&D and SG&A Intensity (5Y)
EBITDA (5Y)
Cost of Revenue (5Y)
Market Cap (5Y)
Ask Blinx with professional market data, charts beside chat, and your portfolio context.
Default quotes are Lang & Schwarz. NASDAQ is the delayed listing price. Charts stay daily. Not investment advice.